Research progress of tumor vascular targeting drugs combined with PD-1/PD-L1 antibody in the treatment of digestive system tumors

In recent years, tumor vascular targeting drugs and programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors have made great progress in tumor therapy. However, monotherapy not only has limited efficacy, but also has drug resistance. The results of many clinical trials at home and abroad showed that the combination of the two were used in the treatment of different tumors of digestive system, such as esophageal cancer, gastric cancer and gastroesophageal junction cancer, liver cancer and so on, so the combination of vascular targeting drugs and PD-1/PD-L1 antibody may be a breakthrough program in tumor therapy because of their good efficacy and safety. Key words: Molecular targeted therapy; Angiogenesis inhibitors; Digestive system neoplasms; PD-1; PD-L1